Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16837304 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL2549786 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL28492074 | 0.81 | CXCR1 (0.67) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL13637085 | 0.81 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL6258808 | 0.81 | KDM4E (0.54) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL23182899 | 0.81 | ALDH1A1 (0.54) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL12477150 | 0.80 | CXCR1 (0.62) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL23348624 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL17863625 | 0.79 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL22907265 | 0.79 | DGAT1 (0.43) | KDM4EALDH1A1SMN1; SMN2CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020263187-A1 | COMPOUNDS FOR TREATMENT OF EYE DISORDERS | SINOPSEE THERAPEUTICS (SG) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020263186-A1 | COMPOUNDS FOR TREATMENT OF CANCER | SINOPSEE THERAPEUTICS (SG) | 2020-12-30 | — | — | WO | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
| EP-2291371-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD11B2 | KDM4E 3785/4885ALDH1A1 186/4885SMN1; SMN2 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.